What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Eric Dein ericdeinmd
3 years 6 months ago
@Rheumnow #EULAR2022 POS0240
▶️ In 2021, 73.6% of Belgian RA patients staring a JAKi, started a 2nd generation JAKi (UPA, FIL).
Predictors for 1st generation usage (BAR, TOFA): older age, prior DMARD therapies.
What would you start as a first JAKi?
Janet Pope Janetbirdope
3 years 6 months ago
Household Cleaning is dirty business at least if you have #rheumatoid #arthritis as silica exposure from laundry and cleaning products were associated with RA ILD. #EULAR opening day. #ClinicalPearl #EULAR2022 @RheumNow #OP0006 https://t.co/OJQMy9Fe9m
Dr. John Cush RheumNow
3 years 6 months ago
Immune Checkpoint Inhibitor Associated Arthritis
Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs).
https://t.co/Eno0TcWlNX https://t.co/XjkBlUEFxk
Eric Dein ericdeinmd
3 years 6 months ago
ACR21: conditionally recommends against steroids with starting csDMARD
#EULAR2022 recommends with rapid GC dose reduction and discontinuation
Which is better recommendation?
@RheumNow
TheDaoIndex KDAO2011
3 years 6 months ago
#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI
TheDaoIndex KDAO2011
3 years 6 months ago
Overarching principles #EULAR2022 AAV Updated reccs are patient centered:
1. Best care w/shared decision making
2. Access to education on AAV
3. Screen pts for Rx side effects/comorbidities
4. Need a multidisciplinary approach w/vasculitis expertise @rheumnow https://t.co/OgE4l4np12
Robert B Chao, MD doctorRBC
3 years 6 months ago
Musculoskeletal US used by dermatologists helped increasedspecificity of PsA detection, leading to fewer false suspicions of PsA earlier diagnosis of psoriatic arthritis.
@RheumNow #EULAR2022 ABST#OP0029
Eric Dein ericdeinmd
3 years 6 months ago
After the #EULAR2022 Recommendations session, it begs the question - Do we follow it?
In Germany, the answer is sometimes
Early bDMARD or JAKi is more frequent in recent years. 1/3 of patients did not receive recommended treatment escalation after 1st csDMARD
POS0234 @Rheumnow https://t.co/0DaP5b7Htc
TheDaoIndex KDAO2011
3 years 6 months ago
Real-world data: #SLE Rx & pt willingness to take risk: 342 pts w/SLE surveyed on hypothetical Rx's based on Sx's. Pts value Sx improvement more than risks & rated most➡️least important: joint pain, rash, & fatigue, risk for infx was least impt #EULAR2022 @Rheumnow POS0086-PARE
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 Update ANCA-associated vasculitis
⭐️Last update 2016
▶️Tissue bx important!
▶️RTX for most for remission, maintenance
▶️Lower steroids (50-75 mg, decrease to 5 mg/d by 4-5 mo), can use avacopan to ⬇️
▶️ No routine PLEX
▶️Maintenance is 24-48 mo, tailor to pt
@RheumNow https://t.co/OmCne2lIIb
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 EGPA recommendations:
Organ or life-threatening? Y = CYC, N = steroid
Relapsing disease? Mepolizumab
@Rheumnow https://t.co/qh564cAhC2
TheDaoIndex KDAO2011
3 years 6 months ago
#EULAR2022 AAV Reccs summarized for induction remission for GPA/MPA @rheumnow https://t.co/Cbp72bCcik
Eric Dein ericdeinmd
3 years 6 months ago
Do you use PJP prophylaxis on patients with ANCA vasculitis on rituximab without high dose steroids?
#EULAR2022 ANCA-associated recommendations
@RheumNow
TheDaoIndex KDAO2011
3 years 6 months ago
#EULAR2022 AAV Reccs for Steroids: start prednisone 50-75 mg/d prednisone and taper to goal 5 mg/day by 4-5 months based on #PEXIVAS @rheumnow https://t.co/6gIfme4HXH
TheDaoIndex KDAO2011
3 years 6 months ago
Overarching principles of #EULAR2022 Ax Spa Updated Reccs @Rheumnow https://t.co/g6Hd9NE1vB
Poster Hall